Enhanced Brain Delivery — transferrin receptor (TfR)-mediated BBB-penetrating bispecific antibody platform developed in collaboration with JCR Pharmaceuticals; focus area: Alzheimer's disease. Lead candidate ACU401 demonstrated up to 40-fold greater frontal cortex exposure in non-human primates with subcutaneous absorption and no hematological safety signals.

Targets: amyloid beta oligomers, AβOs, transferrin receptor, TfR, hTfR

ENHANZE · Halozyme

Halozyme's proprietary drug delivery technology used for subcutaneous formulation of sabirnetug; focus area: Alzheimer's disease.

Biotech Distilled coverage (4)

2026-07-15 UPDATE: Acumen Pharmaceuticals (ABOS) - The EBD Data Just Got Better
2026-03-28 UPDATE: Acumen Pharmaceuticals (ABOS) - 10-K Drop: The Dilution Gap is Officially Closed 🔒 Paid
2026-03-21 UPDATE: Acumen Pharmaceuticals (ABOS) - The Dilution Gap Closes, Smart Money Enters, and the Science Delivers 🔒 Paid
2026-02-18 Acumen Pharmaceuticals (ABOS): Scientific Deep Dive for Sabirnetug 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.